SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Quipt Home Medical Corp. (QIPT) , forward earnings yield 42.74%.
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($1.70, 53.4%).
- Forward P/E 2.3
- Analyst consensus target $1.70 (-53.4% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 30/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — QIPT
Valuation Multiples
P/E (TTM)0.0
Forward P/E2.3
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.46
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.25
Forward EPS (Est.)$1.56
Book Value / Share$0.00
Revenue / Share$7.89
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield42.74%
Dividend Yield0.00%
Analyst Target$1.70 (-53.4%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.23 |
$73.27M |
$-57.37M |
-78.3% |
| 2017 |
$-1.02 |
$61.56M |
$-19.15M |
-31.1% |
| 2018 |
$0.72 |
$59.49M |
$14.51M |
24.4% |
| 2019 |
$-0.27 |
$61.16M |
$-5.58M |
-9.1% |
| 2020 |
$-0.17 |
$72.64M |
$-4.57M |
-6.3% |
| 2021 |
$-0.20 |
$102.35M |
$-6.17M |
-6% |
| 2022 |
$0.13 |
$139.86M |
$4.84M |
3.5% |
| 2023 |
$-0.07 |
$211.68M |
$-2.78M |
-1.3% |
| 2024 |
$-0.16 |
$245.92M |
$-6.76M |
-2.8% |
| 2025 |
$-0.25 |
$341.4M |
$-10.7M |
-3.1% |
